Comparison of the Treatment with Paroxetine and Reboxetine in Panic Disorder: A Randomized, Single-Blind Study
Abstract
INTRODUCTION: Serotonergic agents have greater effectiveness than noradrenergic ones in the treatment of Panic Disorder (PD). However preliminary studies suggested that reboxetine might be effective in the treatment of PD. We compared the effectiveness and tolerability of reboxetine and paroxetine in the treatment of PD. METHODS: Sixty-eight patients with PD were assigned to treatment groups in a single-blind, randomized design. Each patient was assessed at day 0 and 90 by the Panic Associated Symptoms Scale (PASS), the Sheehan Disability Scale (SDS) and the Fear Questionnaire (FQ). Side effects were also recorded. RESULTS: Reduction of PASS scores was significantly greater in the paroxetine group than in the reboxetine one. Vice versa we did not find any significant differences for other outcome measures. Sexual dysfunction and weight gain were significantly less frequent in the reboxetine group. CONCLUSIONS: The results showed a greater effect of paroxetine on panic attacks than reboxetine, while no differences for anticipatory anxiety and avoidance were found, suggesting a different role of noradrenaline and serotonin in the treatment of PD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a randomized single-blind study, paroxetine had a greater effect on clinical panic attacks than reboxetine, whereas no differences were found in anticipatory anxiety and avoidance.
“Similarly, in a randomized single-blind study, we found a greater effect of paroxetine on clinical PAs than reboxetine, whereas no differences were found in anticipatory anxiety and avoidance [37].”
From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [37]
Possible explanations for the weaker anti-panic properties of fluvoxamine and imipramine are that fluvoxamine has the lowest in vitro anticholinergic effects and imipramine has the weakest effect on the serotonergic system.
“Possible explanations are that fluvoxamine has the lowest in vitro anticholinergic effects, which are thought to be involved in respiratory aspects of anti-panic activity [50], whereas imipramine has the weakest effect on the serotonergic system, which plays a crucial role in the pathophysiology of panic–respiration connection [37, 51].”
From Management of Treatment-Resistant Panic Disorder (2017) · cites this paper as [37]
Cited by
Sorted by citations
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · see citing works
“Other antidepressants: Although there is level 1 evidence to support the use of reboxetine [200,219,244], limited experience with this agent in Canada, and its side effect profile, which includes dry mouth, constipation, and insomnia [244], led to its recommendation as a second-line option.”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H., & WFSBP Task Force on Treatment Guide (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 862 · see citing works
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · see citing works
“…is superior to citalopram [I (PCT)] (Bandelow et al., 2007b); and randomised controlled trials suggest that some SSRIs (fluvoxamine, paroxetine) are more effective than some noradrenaline reuptake inhibitors (maprotiline, reboxetine) [II] (Bertani et al., 2004; Den Boer and Westenberg, 1988).”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · see citing works
“, 2003), and some SSRIs (paroxetine, fluvoxamine) to some noradrenaline reuptake inhibitors (reboxetine, maprotiline) (Ib) (Den Boer et al., 1988; Bertani et al., 2004).”
BackgroundDisability and treatment of specific mental and physical disorders across the world
Ormel, J., Petukhova, M., Chatterji, S., Aguilar-Gaxiola, S., Alonso, J., Angermeyer, M. C., Bromet, E. J., Burger, H., Demyttenaere, K., de Girolamo, G., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.039107 · Cited by 389 · see citing works
The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies
Kalk, N. J., Nutt, D., & Lingford-Hughes, A. R. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110367448 · Cited by 123 · see citing works
“Reboxetine has been found to be equivalent to citalopram in reducing the severity of panic attacks in a pilot study (n1⁄4 13 in reboxetine group; n1⁄4 11 in citalopram group) (Bertani et al., 2004; Seedat et al., 2003).”
BackgroundInfluentialDoes the Brain Noradrenaline Network Mediate the Effects of the CO2 Challenge?
Bailey, J., Argyropoulos, S., Lightman, S. L., & Nutt, D. (2003) · Journal of Psychopharmacology · doi:10.1177/02698811030173002 · Cited by 98 · see citing works
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., & Gil‐Ad, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0731-1 · Cited by 80 · see citing works
Mullins, C. D., Shaya, F. T., Meng, F., Wang, J., & Harrison, D. J. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.5.660.63590 · Cited by 78 · see citing works
“The occurrence of these adverse effects differs across SSRIs; for example, paroxetine is associated with weight gain.(4) Adherence to drug therapy is critical in order to obtain a successful clinical outcome.”
BackgroundPollack, M. H., Mangano, R. M., Entsuah, R., Tzanis, E. L., & Simon, N. M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0821-0 · Cited by 73 · see citing works
“The finding from the present study that venlafaxine ER at 225 mg/day, a dose at which its noradrenergic effects become more prominent compared to 75 to 150 mg/day when it is essentially a serotonergic agent, was more effective on a number of measures than the SSRI paroxetine raises the possibility that the combined ef…”
InfluentialEvidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67 · see citing works
“In a single-blind randomized trial (n=68), paroxetine showed larger effects on panic attacks than reboxetine, but no differences were found on anticipatory anxiety and avoidance (Bertani et al. 2004).”
BackgroundPanic disorder: from respiration to the homeostatic brain
Perna, G., Caldirola, D., & Bellodi, L. (2004) · Acta Neuropsychiatrica · doi:10.1111/j.0924-2708.2004.0080.x · Cited by 61 · see citing works
Self-citationAn explorative study on metacognition in obsessive-compulsive disorder and panic disorder
Cucchi, M., Bottelli, V., Cavadini, D., Ricci, L., Conca, V., Ronchi, P., & Smeraldi, E. (2012) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2011.09.008 · Cited by 58 · see citing works
Self-citationHanisch, L. J., Hantsoo, L. V., Freeman, E. W., Sullivan, G. M., & Coyne, J. C. (2008) · Psychological Bulletin · doi:10.1037/0033-2909.134.2.247 · Cited by 47 · see citing works
Evidence-based pharmacotherapy of panic disorder
Bakker, A., van Balkom, A. J. L. M., & Stein, D. J. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005201 · Cited by 44 · see citing works
Choi, Y. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/970730 · Cited by 37 · see citing works
New treatment options for panic disorder: clinical trials from 2000 to 2010
Freire, R. C. R., Hallak, J. E. C., Crippa, J. A. S., & Nardi, A. E. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.562200 · Cited by 37 · see citing works
“The reduction of PASS and other severity scale scores was significantly greater in the paroxetine group than in the reboxetine one [56].”
Management of Treatment-Resistant Panic Disorder
Perna, G., & Caldirola, D. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0128-7 · Cited by 36 · see citing works
Self-citationZulfarina, M. S., Syarifah-Noratiqah, S.-B., Shuid, A. N., Sharif, R., & Mohamed, I. N. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.2.145 · Cited by 31 · see citing works
“, 1996 SARI Nefazodone (50-400) Non-controlled Effective Bystritsky et al.”
BackgroundCurrent Pharmacological Interventions in Panic Disorder
Freire, R. C. R., Machado, S. E. D. C., Arias-Carrión, Ó., & Nardi, A. E. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612125028 · Cited by 27 · see citing works
“Reboxetine [43] and tianeptine [44] had inferior clinical efficacy in the treatment of PD compared to paroxetine.”
BackgroundPharmacological Treatment of Panic Disorder
Bandelow, B., Baldwin, D. S., & Zwanzger, P. (2013) · Modern trends in psychiatry · doi:10.1159/000351953 · Cited by 27 · see citing works
Novel Antidepressants and Panic Disorder: Evidence beyond Current Guidelines
Serretti, A., Chiesa, A., Calati, R., Perna, G., Bellodi, L., & Ronchi, D. D. (2010) · Neuropsychobiology · doi:10.1159/000321831 · Cited by 25 · see citing works
“although reboxetine and citalopram were found to be equally effective in reducing the severity of panic attacks from baseline, citalopram was associated with a significantly higher rate of response. In a second higher-quality study comparing reboxetine to paroxetine [”
ResultSelf-citationTowards a translational model of panic attack.
Schenberg, L. C. (2010) · Psychology & Neuroscience · doi:10.3922/j.psns.2010.1.003 · Cited by 27 · see citing works
“…permissive in panic attacks as suggested by several reports of successful treatments of PD with selective or preferential inhibitors of NE reuptake (Bertani et al., 2004; Dannon, Iancu, & Grunhaus, 2002; Kalus et al., 1991; Lydiard, 1987, Lydiard et al., 1993; Nardi et al., 2003; Sasson et al.,…”
BackgroundEmerging drugs for panic disorder
Perna, G., Guerriero, G., & Caldirola, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.628313 · Cited by 23 · see citing works
“One uncontrolled study suggested a possible efficacy of reboxetine in previous treatmentresistant patients with PD [52], while further comparative studies showed that the rate of full responders was significantly lower in patients with PD treated with reboxetine than in those treated with paroxetine or citalopram [53,…”
ResultSelf-citationDu, Y., Biao, D., Diao, Y. P., Yin, Z., Li, J., Shu, Y., Zhang, Z., & Chen, L. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102664 · Cited by 21 · see citing works
Reboxetine in clinical practice: a review.
Sepede, G., Corbo, M., Fiori, F., & Martinotti, G. (2012) · PubMed · Cited by 21 · see citing works
LADER, M. H. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.2.259 · Cited by 18 · see citing works
Toward a personalized therapy for panic disorder: preliminary considerations from a work in progress
Caldirola, D., & Perna, G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s174433 · Cited by 17 · see citing works
Self-citationPerna, G., Daccò, S., Menotti, R., & Caldirola (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12979 · Cited by 18 · see citing works
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P. R., Kjernisted, K. D., & Ameringen, M. V. (2021) · doi:10.32920/14638581 · Cited by 13 · see citing works
Methods of the World Mental Health Surveys
Kessler, R. C., Heeringa, S. G., Pennell, B., & Zaslavsky, A. M. (2018) · Cambridge University Press eBooks · doi:10.1017/9781107445130.003 · Cited by 18 · see citing works
Evidence-based pharmacotherapy of panic disorder
Batelaan, N. M., van Balkom, A. J. L. M., & Stein, D. J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511910395.006 · Cited by 9 · see citing works
The Neurobiology of Panic Disorder: Toward an Integrated Model
Stein, D. J. (2005) · CNS Spectrums · doi:10.1017/s109285290002650x · Cited by 8 · see citing works
Towards a translational model of panic attack
Schenberg, L. C. (2010) · Psicologia Teoria e Pesquisa · doi:10.1590/s1983-32882010000100003 · Cited by 7 · see citing works
Pharmacologic Treatment of Panic Disorder
Stevens, J., & Pollack, M. H. (2005) · CNS Spectrums · doi:10.1017/s1092852900026511 · Cited by 5 · see citing works
Baldwin, D. S., & Garner, M. J. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00018-5 · Cited by 4 · see citing works
Disability and Treatment of Specific Mental and Physical Disorders
Ormel, J., Petukhova, M. V., Korff, M. R. V., & Kessler, R. C. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511770531.022 · Cited by 4 · see citing works
The Pharmacotherapy of Anxiety Disorders
Bui, É., & Stern, T. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00049-7 · Cited by 2 · see citing works
Pharmacological Treatment of Panic Disorder with Non-Selective Drugs
Cirillo, P. C., & Freire, R. C. R. (2016) · Springer eBooks · doi:10.1007/978-3-319-12538-1_19 · Cited by 1 · see citing works
The Pharmacotherapy of Anxiety Disorders
Bui, É., & Stern, T. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00006-5 · Cited by 1 · see citing works
Katzman, M. A., Bleau, P., Blier, P., Chokka, P. R., Kjernisted, K. D., & Ameringen, M. V. (2021) · doi:10.32920/14638581.v1 · Cited by 1 · see citing works
Current Advances in the Psychopharmacology of Psychosomatic Medicine
Singh, A. N. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7119-6_21
ANTIDEPRESSANTS AND PANIC DISORDER
Neuropsychiatry, C., Andrisano, C., Balzarro, B., Fabbri, C., Chiesa, A., & Serretti, A. (2012)
The Pharmacotherapy of Anxiety Disorders
Pollack, M. H., Kinrys, G., Delong, H., Sa, D. V. E., & Simon, N. M. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04743-2.50043-3
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.634
Capdevielle, D., & Boulenger, J. (2014) · Springer eBooks · doi:10.1007/978-3-642-27772-6_324-2
- Authors
- Bertani, A., Perna, G., Migliarese, G., Di Pasquale, D., Cucchi, M., Caldirola, D., & Bellodi, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2004-09
- Volume
- 37
- Issue
- 5
- Pages
- 206-210
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W1971722560
- Cited by
- 49
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2021: 3 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 2 · 2014: 4 · 2013: 2 · 2012: 3
- FWCI
- 4.64
- Type
- journal article
- Language
- de
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- panic disorder, paroxetine, reboxetine, serotonergic agents, noradrenergic agents, antidepressant efficacy, tolerability, sexual dysfunction, weight gain, anticipatory anxiety, avoidance, norepinephrine, serotonin
- MeSH terms
- Reboxetine, Adult, Female, Humans, Male, Morpholines, Psychometrics, Single-Blind Method, Panic Disorder, Selective Serotonin Reuptake Inhibitors, Paroxetine, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
